A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

Also called NCT07833098

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT07833098
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07833098. Randomized; quadruple masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
Condition
Hypertension
Condition
Resistant Hypertension
Condition
Uncontrolled Hypertension
Intervention (Drug)
VB19055 Dose A QD
Intervention (Drug)
VB19055 Dose B QD
Intervention (Drug)
VB19055 Dose C QD
Intervention (Drug)
VB19055 placebo QD
Lead sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07833098
Content hash
66e41694037190f3950904c22c512ce3270e1fe1e320c1c8e2919f16c9e0f809